Media headlines about Patheon (NYSE:PTHN) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Patheon earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.4806981615968 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Patheon (PTHN) remained flat at $$34.98 during mid-day trading on Thursday. The company had a trading volume of 229,700 shares, compared to its average volume of 754,718. The company has a debt-to-equity ratio of -7.33, a quick ratio of 0.91 and a current ratio of 1.65. Patheon has a one year low of $23.72 and a one year high of $35.13. The firm has a market cap of $5,076.86, a PE ratio of 46.64 and a beta of 2.70.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Patheon (PTHN) Share Price” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://transcriptdaily.com/2018/01/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-patheon-pthn-share-price.html.
Patheon Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon and related companies with MarketBeat.com's FREE daily email newsletter.